Roivant Sciences Ltd.
ROIV
$11.41
$0.3252.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.08% | -42.05% | 22.67% | 78.23% | -67.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.08% | -42.05% | 22.67% | 78.23% | -67.05% |
| Cost of Revenue | 36.90% | 39.81% | 22.95% | 7.72% | -- |
| Gross Profit | -41.83% | -54.86% | -22.96% | -4.73% | -- |
| SG&A Expenses | 128.37% | 31.07% | 32.29% | 1.87% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.24% | 35.43% | 27.01% | 5.07% | -21.37% |
| Operating Income | -85.71% | -41.92% | -27.09% | -3.41% | 16.03% |
| Income Before Tax | -101.58% | -104.55% | 7.05% | 91.94% | -- |
| Income Tax Expenses | 954.34% | -214.32% | 284.98% | 614.21% | -- |
| Earnings from Continuing Operations | -165.78% | -104.07% | 3.19% | 87.11% | -- |
| Earnings from Discontinued Operations | 100.00% | 658.87% | 50.18% | 207.84% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 46.27% | 118.15% | 85.66% | 4.93% | -- |
| Net Income | -36.63% | -96.68% | 24.36% | 132.66% | -349.52% |
| EBIT | -85.71% | -41.92% | -27.09% | -3.41% | 16.03% |
| EBITDA | -95.25% | -42.81% | -29.73% | -4.01% | 19.88% |
| EPS Basic | -55.10% | -96.32% | 20.78% | 133.70% | -315.45% |
| Normalized Basic EPS | -257.53% | -19.54% | 29.20% | 52.67% | -- |
| EPS Diluted | -56.00% | -96.14% | 20.78% | 131.12% | -311.82% |
| Normalized Diluted EPS | -257.53% | -26.06% | 29.20% | 52.67% | -- |
| Average Basic Shares Outstanding | -11.90% | -9.73% | -4.51% | -3.10% | 12.64% |
| Average Diluted Shares Outstanding | -11.90% | -14.42% | -4.51% | -3.10% | 12.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |